Currently the gold standard for allergy diagnosis is to feed the child peanut in a hospital setting where anaphylactic attacks can be clinically managed when they occur. This approach is a stressful and often traumatic experience for the children being tested. This grant seeks to develop an in-house assay with the potential for a population-wide screening test to reduce unexpected morbidity and deaths from peanut anaphylaxis. For the first time doctors will be have a biomarker test capable of differentiating between allergic patients who are at risk of a life-threatening anaphylactic response upon exposure to peanut vs less severe clinically significant allergy, thus reducing stress and trauma for children and families.
Food allergies cause an enormous health burden to our community and peanut allergy is the most severe and persistent food allergy.